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Topical Antihistamines Display Potent
Anti-Inflammatory Activity Linked in Part to
Enhanced Permeability Barrier Function
Tzu-Kai Lin1,2,11, Mao-Qiang Man1,11, Juan-Luis Santiago1,3,11, Kyungho Park1, Truus Roelandt1,4, Yuko Oda1,
Melanie Hupe1, Debra Crumrine1, Hae-Jin Lee5, Maria Gschwandtner6, Jacob P. Thyssen1,7, Carles Trullas8,
Erwin Tschachler6, Kenneth R. Feingold9,10 and Peter M. Elias1
Systemic antagonists of the histamine type 1 and 2 receptors (H1/2r) are widely used as anti-pruritics and central
sedatives, but demonstrate only modest anti-inflammatory activity. Because many inflammatory dermatoses result
from defects in cutaneous barrier function, and because keratinocytes express both Hr1 and Hr2, we
hypothesized that H1/2r antagonists might be more effective if they were used topically to treat inflammatory
dermatoses. Topical H1/2r antagonists additively enhanced permeability barrier homeostasis in normal mouse
skin by the following mechanisms: (i) stimulation of epidermal differentiation, leading to thickened cornified
envelopes; and (ii) enhanced epidermal lipid synthesis and secretion. As barrier homeostasis was enhanced to a
comparable extent in mast cell–deficient mice, with no further improvement following application of topical
H1/2r antagonists, H1/2r antagonists likely oppose mast cell–derived histamines. In four immunologically diverse,
murine disease models, characterized by either inflammation alone (acute irritant contact dermatitis, acute
allergic contact dermatitis) or by prominent barrier abnormalities (subacute allergic contact dermatitis, atopic
dermatitis), topical H1/2r agonists aggravated, whereas H1/2r antagonists improved, inflammation and/or barrier
function. The apparent ability of topical H1r/2r antagonists to target epidermal H1/2r could translate into
increased efficacy in the treatment of inflammatory dermatoses, likely due to decreased inflammation and
enhanced barrier function. These results could shift current paradigms of antihistamine utilization from a
predominantly systemic to a topical approach.
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INTRODUCTION
Because of their common embryological origin, the epidermis,
not surprisingly, expresses multiple neuroreceptors, neuro-
transmitters, and neurohormones that mediate important
functions in the central nervous system (Denda, 2002;
Denda et al., 2007). One of these mediators is histamine
(Travis et al., 2000), an aminergic neurotransmitter that is
produced not only by neurons but also by mast cells,
eosinophils, and basophils (Endo et al., 1992; Endo et al.,
1995; Yamaguchi et al., 2000). In contrast to the limited
number of cell types that synthesize histamines, one or more
of four histamine receptors (H1r-4r), belonging to the
superfamily of G-protein-coupled receptors, are ubiquitous
and modulate a variety of pathophysiological responses,
including pruritus and inflammation in the skin (Hill et al.,
1997; Oda et al., 2000). Yet, although systemic antihistamines
are widely deployed in clinical settings, they demonstrate only
modest anti-inflammatory activity in diseases such as atopic
dermatitis (AD; Klein and Clark, 1999; Diepgen, 2002;
Kawashima et al., 2003; Buddenkotte et al., 2010; Eschler
and Klein, 2010). Moreover, their utilization can be limited by
important side effects, including sedation and cardiotoxicity,
particularly in the elderly (reviewed in Greaves (2005)). The
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reason for the limited anti-inflammatory activity of systemic
antihistamines is not known, but it seems plausible that either
their bioavailability to peripheral tissues could be limited at
current dosage levels or they could be substantially
metabolized before their arrival in the skin. Because the H1r
and H2r are strongly expressed in the epidermis
((Gschwandtner et al., 2011) and these studies), and because
one previous study showed that topical H1/2r antagonists
improve barrier function in normal skin (Ashida et al., 2001),
we hypothesized here that the bioavailability and efficacy of
antihistamines could be enhanced were they deployed as
topical rather than as systemic agents to treat inflammatory
dermatoses, with or without associated barrier abnormalities.
The epidermis mediates a set of protective functions,
including maintenance of permeability barrier homeostasis.
This critical function, which allows survival in a terrestrial
environment, is mediated by the unique two-compartment
organization of the stratum corneum (SC) into anucleate
corneocytes embedded in an expanded, lipid-enriched extra-
cellular matrix (reviewed in Elias and Menon (1991)).
Inflammatory dermatoses are now increasingly recognized to
result from inherited abnormalities that compromise epidermal
barrier function (Sandilands et al., 2009; Irvine et al., 2011). A
likely pathogenic sequence that leads to inflammation invokes
both increased allergen penetration, through a genetically
impaired barrier, leading to Th2 (T helper type 2)
inflammation (Irvine et al., 2011), and an epidermis-initiated
‘‘cytokine cascade’’ that recruits downstream inflammation
(Wood et al., 1992; Nickoloff and Naidu, 1994). Accordingly,
immune abnormalities, once seen as the primary disease
instigator, are now increasingly considered as downstream or
disease-modifying participants (Elias et al., 2008a, Elias
and Steinhoff, 2008). Further, inflammation once established
can further aggravate the barrier abnormality by multiple
mechanisms, establishing an ‘‘outside-to-inside, back-
to-outside’’ pathogenic circle (Elias et al., 2008a; Elias and
Steinhoff, 2008; Elias and Schmuth, 2009). Accordingly,
disorders such as AD, psoriasis, and the inherited ichthyoses
are increasingly being treated with various forms of topical
‘‘barrier repair therapy,’’ strategies that can themselves be anti-
inflammatory by multiple mechanisms (reviewed in Elias and
Wakefield (2011)). We show here that topical antihistamines
could comprise effective therapy not only through enhanced
anti-inflammatory activity but also partly through their ability
to improve epidermal structure and function. As mast cell–
deficient mice (MCDM) displayed a comparable enhancement
in barrier function, and as topical H1/2r antagonists provided
no further benefits, the H1/2r antagonists likely oppose mast
cell–derived histamines. Finally, the H1r and H2r antagonists
markedly improved inflammation in four different inflamma-
tory dermatoses models, characterized by inflammation alone
and/or a prominent barrier abnormality.
RESULTS
Topical antihistamines enhance cutaneous permeability barrier
homeostasis by opposing mast cell–derived histamines
As recently reported by Gschwandtner et al. (2011), we
initially found that only the H1r and H2r are expressed in
abundance in normal mouse epidermis (Supplementary Figure
S1 online). We used the H1r and H2r antagonists, diphenhy-
dramine and cimetidine, because they most potently improved
barrier function among several agents tested in preliminary
studies. Twice-daily topical applications of these H1/2r antago-
nists to intact skin produced only modest changes in basal
barrier function, SC hydration, and surface pH, which all fell
within the normal range (Figure 1a–c). By contrast, when skin
0.10
P<0.01
0.05
0.00
Vehicle H1r H2r
Tr
a
n
se
pi
de
rm
a
l w
a
te
r
lo
ss
 (m
g 0
.5 
cm
–
1  
hr
–
1 )
ba
6
5
Su
rfa
ce
 p
H
4
*
*
3
2
1
*P<0.01 vs. vehicle
Vehicle H1r H2r
c
80
70
60
50
SC
 c
ap
ac
ita
nc
e 
(au
)
P<0.01
Vehicle H1r H2r
d
0
100
200
Vehicle (n =24–29)
H1r (n =25–31)
H2r (n =6–13)
H1r+H2r (n =19)
300
4 Hours
Ba
rri
er
 re
co
ve
ry
 ra
te
s
(%
 of
 ve
hi
cl
e)
e WT (n =12)
MCDM (n =12)
0
100
200
P
=
0.
06
7
300
2 Hours 4 Hours
Ba
rri
er
 re
co
ve
ry
 ra
te
s
(%
 of
 w
ild
 ty
pe
)
P=
0.
00
18
2 Hours
**
,
***
***
***
***
* *
Figure 1. Topical H1/2r (histamine type 1 and 2 receptors) antagonists enhance permeability barrier homeostasis in normal skin. The flanks of hairless
mice (n¼4–5 each) were treated with topical applications of either diphenhydramine chlorhydrate (H1r), cimetidine (H2r), or ethanol (vehicle) twice daily
for 4 days (see Materials and Methods for further details). At the end of treatments, changes in basal barrier function, assessed as (a) transepidermal water loss
(TEWL), (b) surface pH, and (c) electrical conductance (SC) hydration, were measured. (d) Barrier disruption was induced by sequential cellophane tape strippings
until TEWL levels X10-fold increase over baseline, and barrier recovery rates were assessed 2 and 4 hours later (**Po0.05 vs. vehicle, *Po0.01 vs. vehicle,
***Po0.001 vs. vehicle and vs. H1rþH2r). (e) Percentage of barrier recovery was compared in mast cell–deficient KitW/KitW-v double-heterozygote mice (MCDM)
with wild-type (WBB6F1) mice 2 and 4 hours after tape stripping, as described above.
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sites, previously treated with H1/2r antagonists, were disrupted
by sequential tape stripping, permeability barrier restoration
accelerated (by E100%) in comparison with vehicle-treated
sites (Figure 1d). Moreover, coapplications of the H1r and H2r
antagonists additively improved barrier function at 2 hours
after barrier disruption, but no additive or synergic effects were
observed at 4 hours after barrier abrogation (Figure 1d). Finally,
when the H1r and H2r antagonists were applied unilaterally
(vehicle alone applied to the opposing, similarly tape-stripped
flank), barrier homeostasis improved only on the antagonist-
treated side (not shown), indicating that the H1/2r antagonists
enhance epidermal function locally, rather than after previous
systemic absorption.
The putative sources for endogenous histamine in the skin
are cutaneous mast cells, which are present in substantial
numbers in normal skin (Janssens et al., 2005). To assess
whether the H1/2r antagonists improve barrier function by
opposing mast cell–derived histamine, we next compared
barrier homeostasis in MCDM (kitw/kitw-v) with age-matched,
same-strain (WBB6F1), mast cell–replete mice. Although basal
barrier function, hydration, and surface pH did not differ in
MCDM compared with wild-type mice, barrier recovery
accelerated significantly (E160%) in MCDM at 2 hours
compared with control mouse skin (Figure 1e; Po0.002), an
enhancement of barrier homeostasis that was comparable with
that produced by the topical antihistamines. However, no
further improvements in permeability barrier homeostasis
occurred when MCDM were treated topically with either the
H1r or H2r antagonist (Supplementary Figure S2 online).
Interestingly, barrier disruption provoked a modest, although
significant, increase in the density of mast cells
(Supplementary Figure S3 online). Together, these results show
that (1) topical H1r and H2r antagonists improve permeability
barrier homeostasis in acutely perturbed, but otherwise nor-
mal, mouse skin (see also Ashida et al. (2001)); (2)
improvement is due to local effects, ruling out the efficacy
due to previous systemic absorption; (3) mast cell–derived
histamine is likely the primary source of ligand opposed by the
H1/2r antagonists; (4) barrier disruption stimulates prolifera-
tion of mast cells in the dermis; and (5) H1/2r antagonists
improve barrier function specifically by opposing mast cell–
derived histamines.
Mechanisms whereby topical antihistamines enhance barrier
function
Corneocytes and extracellular lipids together mediate epidermal
permeability barrier homeostasis (Elias, 2006; Feingold, 2007).
To explore the mechanistic basis for enhanced permeability
barrier function, we first assessed whether these agents alter
epidermal proliferation after barrier disruption. In hematoxylin
and eosin–stained sections, both H1r and H2r antagonists
modestly stimulated epidermal hyperplasia (Supplementary
Figure S4a–c online), but the increase in thickness achieved
statistical significance only in H2r antagonist–treated skin
(Supplementary Figure S4d–g online). Similarly, epidermal
proliferation, assessed as the density of PCNA-positive cells in
the basal layer, increased more in H2r than in H1r antagonist–
treated skin (Supplementary Figure S4h online).
We next assessed whether one or both of these agents
enhance the expression of epidermal differentiation–related
proteins. Applications of the H1/2r antagonists to intact skin
enhanced the expression of involucrin, loricrin, and particu-
larly filaggrin in immunohistochemical preparations
(Figure 2a–i). Accordingly, epidermal mRNA levels, assessed
by real-time quantitative PCR (see Supplementary Table S1
online for a list of all the primers used in the studies),
increased after H1/2r antagonist applications (Figure 2j).
Finally, we assessed whether increased differentiation-linked
protein expression translated into an altered corneocyte
structure. Electron microscopy demonstrated an apparent
increase in the thickness of cornified envelopes in both H1r
and H2r antagonist–treated epidermis (Figure 3a–c), validated
further in quantitative studies, using randomized, coded
micrographs (E 40% increase; Po0.0001 for both H1/2r
antagonists) (Figure 3d). Together, these studies show that the
H1r/H2r antagonist–induced improvements in barrier function
can be partly attributed to enhanced epidermal differentiation,
leading to more robust corneocytes.
Epidermal permeability barrier function requires both the
synthesis and ultimately the secretion of hydrophobic lipids
from epidermal keratinocytes into the SC extracellular matrix
(Feingold, 2009). Therefore, we next asked whether topical
H1r and H2r antagonists enhance lipid production and/or
secretion in normal epidermis. To assess the global impact of
the antihistamines on lipid production, we initially compared
fluorescence intensity after applications of nile red, a
fluorophore that selectively depicts lipids, with frozen
sections of topical H1/2r antagonist–treated normal skin. Both
H1r and H2r antagonists markedly enhanced the overall lipid
content of the epidermis (Figure 4a–c, arrows; H2r4H1r).
We next assessed whether topical H1/2r antagonist treat-
ments enhance epidermal lipid synthesis. After 4 days of
topical treatment, both the H1r and H2r antagonists signifi-
cantly stimulated both epidermal non-saponifiable lipid and
cholesterol synthesis, but only the H1r antagonist upregulated
saponifiable lipid (i.e., fatty acid) synthesis (Figure 4d). To
assess the basis for enhanced lipid synthesis, we next com-
pared changes in expression of several key lipid synthetic and
lipid-modifying enzymes in the epidermis 2 hours after topical
H1/2r antagonist applications. By real-time quantitative PCR,
mRNA levels of HMGCoA reductase and serine palmitoyl
transferase, the rate-linking enzymes of cholesterol and sphin-
goid base (ceramide) synthesis, respectively, increased sig-
nificantly after topical H1/2r antagonist applications (Figure 4e
and f). Moreover, mRNA levels for two key enzymes that
modify fatty acid structure, the a-hydroxylating enzyme, (fatty
acid 2-hydroylase), and the elongation enzyme (elongation of
very long-chain fatty acid-4), which is required for acylcer-
amide production, increased significantly after H1/2r antago-
nist applications (Figure 4g and h). Together, these results
demonstrate that both H1r and H2r antagonists stimulate
epidermal lipid production by multiple pathways.
Newly synthesized lipids are packaged into epidermal
lamellar bodies, which then deposit their cargo at the stratum
granulosum–SC interface. To determine whether the antihis-
tamines stimulate lipid secretion, we next assessed changes in
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lamellar body formation after topical H1/2r antagonist appli-
cations to intact skin (Figure 5a–f). Although the density of
lamellar bodies in the granular cell cytosol appeared to
increase after treatment with the H2r antagonist, the H1r
antagonist instead appeared to stimulate premature secretion
of lamellar body contents between cells deep within the
granular layer, a feature that was not evident following H2r
antagonist applications (Figure 5e vs. c). To determine the
basis for enhanced lamellar body production, we next
assessed mRNA levels of the epidermal-specific, transmem-
brane transporter, ABCA12, which delivers glucosylceramides
into nascent lamellar bodies. Transporter mRNA levels
increased significantly after H2r antagonist applications, a
finding that correlated with increased lamellar body density in
parallel samples (cf., Figure 5e; increase after H1r antagonist
applications did not achieve statistical significance, Figure 5f).
Finally, accelerated production, with or without premature
secretion, correlated with enhanced deposition of lamellar
body contents at the stratum granulosum–SC interface, a
change more evident in H2r than in H1r antagonist–treated
epidermis (Figure 5b and d, open arrows). Together, these
results suggest that the H1/2r antagonists also improve barrier
function by stimulating lipid secretion.
Topical antihistamines improve inflammation and barrier
function in diverse murine models
The studies mentioned above show that topical H1/2r antago-
nists substantially enhance epidermal structure and function in
otherwise normal skin by multiple mechanisms. Many inflam-
matory skin diseases are characterized not only by inflamma-
tion but also by permeability barrier abnormalities. A primary
barrier abnormality can induce inflammation (Elias and
Schmuth, 2009; Elias, 2010); conversely, a primary
immunologic abnormality, as in HIV (Gunathilake et al.,
2010), can lead to abnormalities in barrier function that
further stimulate inflammation (Elias et al., 1997; Elias et al.,
1999; Elias and Feingold, 2001). Hence, we next asked
whether topical H1/2r antagonists could have favorable
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Figure 2. Topical H1/H2r (histamine type 1 and 2 receptors) antagonists stimulate epidermal differentiation. (a–i) Hairless mice were treated as described
above, and paraffin-embedded sections (6mm) were then immunostained to detect changes in filaggrin, involucrin, and loricrin content and localization. (j) In parallel,
mRNA was isolated from freshly obtained epidermal sheets after treatments as in Figure 1, above (n¼4), and changes in mRNA levels for filaggrin, loricrin, and
involucrin were assessed by real-time quantitative PCR (see Materials and Methods and Supplementary Table S2 online for further details). Bar¼ 50mm. Veh, vehicle.
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effects in four different mouse models of cutaneous disease
(Supplementary Table S2 online).
Acute irritant contact dermatitis (AICD). AICD, induced by
topical phorbol ester (12-O-tetradecanoylphorbol-13-acetate)
treatment, is characterized by inflammation, but barrier function
remains within the range of normal, even after inflammation
appears (2 hours; 8.1±2.4 vs. 6.4±1.9 (SD); n¼ 29–31; normal
p10; Supplementary Table S2 online). A single application of
either the H1r or H2r antagonist, immediately after the phorbol
ester application, significantly reduced inflammation in AICD,
quantified as reductions in ear thickness (Figure 6a). In parallel,
dermal inflammation and epidermal hyperplasia, assessed in
hematoxylin and eosin–stained sections, declined markedly
(Supplementary Figures S5 and S6 online). By contrast, pretreat-
ment with H1/2r antagonists before application of 12-O-tetra-
decanoylphorbol-13-acetate did not prevent inflammation (ear
thickness, 0.32þ 0.01 for vehicle, 0.29þ 0.01 for H1r antagonist,
and 0.34þ 0.01 for H2r antagonist).
Acute allergic contact dermatitis. Acute allergic contact derma-
titis, produced by a single hapten (oxazolone) challenge, after
previous sensitization, also induces inflammation (Supplementary
Figure S6 online), without provoking an immediate barrier abnorm-
ality (Sheu et al., 2002; Fowler et al., 2003; 3.9±1.7 vs. 3.4±1.5
(SD); n¼ 26–31; Po0.5). Both H1r and H2r antagonists markedly
reduced histological evidence of inflammation (Supplementary
Figure S5 online), further quantified as a reduction in ear thickness
in acute allergic contact dermatitis (Figure 6a). Yet pretreatment
again did not prevent the development of inflammation (not
shown). Together with the studies in AICD, these results demon-
strate that topical H1/2r antagonists exhibit potent anti-inflamma-
tory activity in dermatoses that lack a primary barrier abnormality.
Subacute allergic contact dermatitis (SACD). SACD, induced by
repeated hapten challenges (3x), is characterized by both a
substantial barrier abnormality (Figure 6b) as well as inflamma-
tion. Treatment with both the H/2r antagonists significantly
improved barrier function and decreased inflammation in the
SACD model (Figure 6b; but pretreatment with the antagonists
again did not prevent the development of inflammation).
AD–like dermatosis. With further hapten challenges (10x), AD–
like inflammation develops, in which a prominent barrier
abnormality is currently thought to ‘‘drive’’ downstream inflam-
mation, characterized by a prominent Th2-dominant immuno-
phenotype (Supplementary Table S2 online; Elias et al., 2008a,
Elias and Steinhoff, 2008; Irvine et al., 2011). When we applied
specific H1/2r receptor agonists, both exacerbated inflammation
in the AD model (Supplementary Figures S6 and S7 online). By
contrast, H1r and H2r antagonists reduced inflammation
(Supplementary Figures S6 and S7 online), but only the H2r
antagonist significantly improved barrier function in this model
(Figure 6b). As the H1/2r antagonists improved inflammation and
barrier function only at sites of local application in both the SACD
and AD models, systemic activity did not account for disease
improvement. Yet again, neither antagonist exhibited preventive
benefits in these models. These results show that H1/2r antago-
nists improve inflammation in the AD model, often with parallel
improvements in barrier function.
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Figure 3. Topical H1r/H2r (histamine type 1 and 2 receptors) antagonists enhance corneocyte envelope (CE) thickness. (a–c) Electron micrographs of biopsies
of H1/2r antagonist–treated skin were processed for electron microscopy, as described in Methods. (d) Ten micrographs each of perpendicular sections taken
at random from six different biopsy samples. CE dimensions were measured directly on the electron microscope, as described in Materials and Methods.
a–c; Osmium tetroxide postfixation. Bar¼ 100mm. Veh, vehicle.
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DISCUSSION
Although histamine is a potent inflammatory mediator, whose
levels increase markedly in inflammatory dermatoses (reviewed
in Pavlinkova et al. (2003) and Greaves (2005)), systemic
antihistamines have proven ineffective as anti-inflammatory
therapy for these disorders (Belsito et al., 1990; Klein and Clark,
1999; Diepgen, 2002; Kawashima et al., 2003; Buddenkotte
et al., 2010). Thus, these agents are largely deployed for their
relatively modest anti-pruritic or central sedating properties
(Buddenkotte et al., 2010; Eschler and Klein, 2010). Yet their
use for these purposes can be limited by important side effects,
particularly in the elderly (Greaves, 2005). Systemic
antihistamines could be minimally effective, because of poor
peripheral bioavailability and/or metabolism to inactive
compounds before their arrival in the skin (Levi-Schaffer and
Eliashar, 2009). Although topical antihistamines are widely
used as anti-pruritics (Eschler and Klein, 2010; Baumer et al.,
2011), whether the topical approach could provide further
anti-inflammatory benefits has not yet been examined.
After showing that H1r and H2r are highly expressed in the
epidermis, we hypothesized that topical deployment of H1/H2r
antagonists could provide a boost in anti-inflammatory activity,
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Figure 4. Global stimulation of epidermal lipid synthesis by topical H1/2r (histamine type 1 and 2 receptors) antagonists. Hairless mice were treated as described
above (Figure 1), and biopsies were snap-frozen in liquid nitrogen. (a–c) Frozen sections (5mm) were incubated with either the fluorophore, nile red, or vehicle,
and viewed under a fluorescence microscope, as described in Materials and Methods (arrows depict sites of enhanced staining for lipids in the epidermis).
(d) Freshly obtained, full-thickness skin biopsies were incubated with 14C-acetate, followed by epidermal isolation, lipid extraction, saponification, fractionation by
thin-layer chromatography, and quantification of changes in non-saponifiable (NSL) and saponifiable (total fatty acid) lipids, as described in Materials and Methods.
(e–j) mRNA was isolated from epidermal sheets as described above (n¼4 mice each), and changes in mRNA levels for lipid synthetic enzymes (HMGCoA
reductases, serine palmitoyl transferase (SPT), fatty acid modifying enzyme, fatty acid 2-hydroxylase (FA2H), and the acylceramide-generating elongation of very-long
chain fatty acid-4 (ELOVL4)) were assessed by real-time quantitative PCR, as described in Materials and Methods and Supplementary Table S2 online. Bar¼10mm.
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because of their greater bioavailability, and perhaps by improv-
ing barrier function. Pertinently, several inherited inflammatory
dermatoses, includingAD, inflammatory ichthyoses, and even
psoriasis, are now seen as barrier initiated (Sun et al., 2006;
Schmuth et al., 2007; Tschachler, 2007; Elias et al., 2008b,
Chen et al., 2009; Sandilands et al., 2009; Elias et al., 2010;
Strange et al., 2010). Hence, after initially determining whether
and how these agents improve barrier function in the normal
epidermis, we then assessed their efficacy in several unrelated
mouse models of inflammatory dermatoses.
We described here a markedly improved barrier function
following topical H1r and H2r antagonist applications to
normal skin, confirming prior studies (Ashida et al., 2001).
We further demonstrated that H1r and H2r additively
improved barrier function, at least at early time points.
These results suggest that H1r and H2r could regulate
epidermal function via different downstream mechanisms.
Moreover, these agents appear to target the appropriate
receptors, as H1/2r antagonist applications to MCDM
provided no further benefits for the barrier. As the MCDM
also demonstrated enhanced barrier function, and as topical
H1/2r antagonists exert no further benefits, these results
strongly suggest that mast cells must be the primary source
of the ligand that is opposed by the H1/2r antagonists. Yet
these studies did not completely rule out other cell types as
potential sources of histamine.
How these agents enhance the epidermal structure and
function is not yet known. We identified several mechanisms
that account for enhanced permeability barrier in H1/2r
antagonist–treated normal skin. First, acute barrier disruption
increased the density of mast cells in the dermis, raising the
question whether recruitment of mast cells to the skin
contributes to the development of inflammation in dermatoses
characterized by barrier abnormalities. But perhaps more
importantly, the topical H1/2r antagonists directly impact
epidermal structure and function. Topical applications of
H1r and H2r antagonists enhanced epidermal differentiation,
the latter at both the mRNA and protein levels, which could
reflect the ability of these agents to mobilize intracellular
calcium (Koizumi and Ohkawara, 1999). Enhanced
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aggregated lamellar bodies, and open arrows depict changes in secreted contents at the stratum granulosum (SG)–SC interface. Representative samples of the outer
epidermis of (a) vehicle-treated (Veh), (b and c) H1r antagonist (diphenhydramine chlorhydrate)–treated, and (d) H2r (cimetidine)-treated skin. Note increased
organelle density in the SG of H2r-treated epidermis, and premature secretion of lamellar bodies in H1r antagonist–treated skin, (b–e), as well as enhanced
secretion of lamellar body contents at the stratum granulosum (SG)–SC interface (H2r4H1r). (f) Enhanced formation of lamellar bodies correlated with
increased mRNA levels of ABCA12 in H2r antagonist–treated skin (n¼ 4); the increase in ABCA12 mRNA following H1r antagonist treatments did not
achieve statistical significance. a–e: Osmium tetroxide postfixation. Bar¼0.5mm. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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differentiation translated further into a significant increase in
the thickness of cornified envelopes, which should yield more
robust corneocytes, also a Caþ þ -dependent process (Kim and
Bae, 1998; Nemes and Steinert, 1999). The converse certainly
proves this point—effete cornified envelopes occur in several
inherited disorders of cornification, including loss-of-function
mutations in transglutaminase 1–deficient (lamellar) ichthyosis
(reviewed in Schmuth et al. (2007)), that display subnormal
barrier function. Thus, the more robust corneocytes in topical
H1/H2r antagonist–treated skin likely contribute to enhanced
barrier function.
We also show that topical antihistamines enhance barrier
function by stimulating the synthesis and secretion of epider-
mal lipids. Multiple steps in the initial synthesis, later mod-
ification, and subsequent secretion of epidermal lipids were
stimulated by topical applications of the H1r and/or H2r
antagonists. Pertinently, hepatic lipid synthesis is similarly
enhanced in both H1r and H2r knockout mice (Wang et al.,
2010). Yet there were subtle differences in the effects of H1r
and H2r antagonists on these metabolic pathways in normal
epidermis. Although both the H1r and H2r antagonists
stimulate epidermal lipid synthesis, the H2r antagonists more
potently stimulate lamellar body production, which parallel
the enhancement of ABCA12 expression after H2r (but not
H1r) antagonist applications. Although the H1r antagonist
displayed a lesser impact on organelle production (and
ABCA12 expression), it instead appeared to accelerate
lamellar body secretion. Thus, in addition to profound effects
on epidermal differentiation, H1/2r antagonists strongly
stimulate epidermal lipid synthesis, metabolism, and secretion.
On the basis of the putative link between abnormalities in
barrier function and downstream inflammation, we reasoned
that topical antihistamines could reduce inflammation in
inflammatory dermatosis, at least in part by improving barrier
function, as we showed previously with activators of the
liposensor subclass of nuclear hormone receptors (i.e., PPARa,
g, b/d and LXR). These agents not only improve barrier function
in normal skin (Man et al., 2006; Schmuth et al., 2008) but also
reduce inflammation in diverse inflammatory dermatosis
models that may or may not be characterized by a barrier
abnormality (Komuves et al., 2000; Sheu et al., 2002; Fowler
et al., 2003). Indeed, our results strongly suggest that the
benefits of the topical H1/2r antagonists extend beyond their
impact on barrier function, because they also reduced
inflammation in two models, in which barrier function
remained normal (i.e., AICD and acute allergic contact
dermatitis). Thus, the topical H1/2r antagonists exhibit potent
anti-inflammatory activity that could operate independently of,
or in parallel to, improved barrier function. By contrast, the
SACD and AD models display progressively more severe
barrier abnormalities ((Man et al., 2008; Hatano et al., 2009;
Hatano et al., 2010) and these results). As both the H1r and
H2r antagonists improve barrier function in both of these
models, it is tempting to argue that this result reflects the
impact of the antagonists on barrier function. The H1r
antagonist, although highly anti-inflammatory, did not
significantly improve barrier function in the AD model.
Hence, it is not possible to discriminate which of these two
mechanisms (anti-inflammatory versus barrier enhancement)
predominates in reducing inflammation. Yet even the anti-
inflammatory benefits could reflect direct effects on the
epidermis, because both the H1r and H2r antagonists oppose
production of multiple keratinocyte-derived cytokines (Shimizu
et al., 2004; Matsubara et al., 2005; Kobayashi et al., 2009),
independent of their well-known ability to stabilize histamine
production by mast cells (Levi-Schaffer and Eliashar, 2009).
Moreover, anti-inflammatory benefits can accrue with
improved barrier function via a reduction in the barrier-
initiated ‘‘cytokine cascade’’ (Elias et al., 2008a; Elias and
Steinhoff, 2008). Pertinently, topical H1/2r agonists instead
aggravated inflammation, perhaps by direct proinflammatory
effects, or by further compromising barrier function, as they do
after topical applications to normal skin ((Ashida et al., 2001)
and these studies).
Not only filaggrin-deficient AD (Sandilands et al., 2009) but
also all of the inherited ichthyoses studied to date (Schmuth
et al., 2007; Elias et al., 2008b, Elias et al., 2010), and most
recently even psoriasis (Sun et al., 2006; Tschachler, 2007;
Chen et al., 2009; Strange et al., 2010), appear to be provoked
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Figure 6. Topical H1/2r (histamine type 1 and 2 receptors) antagonists
improve inflammatory dermatosis, independent of benefits for barrier
function. (a) Changes in ear thickness in acute irritant and acute allergic
contact dermatitis (AICD and AACD, respectively) 16 hours after previous
topical application of the H1/2r antagonists. (b) Changes in transepidermal
water loss 16 hours after a single topical application of the H1r or H2r
antagonist or vehicle (veh) to opposing flanks of previously sensitized and
subsequently challenged mice (3x¼ subacute allergic contact dermatitis
(SACD)); (atopic dermatitis (AD)¼10 hapten challenges). Dotted line indicates
upper level of water loss in normal mice.
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by primary genetic alterations that compromise epidermal
structure and function. As these dermatoses are often driven or
accompanied by prominent barrier abnormalities, not
surprisingly, recent studies show that a variety of ‘‘barrier
repair’’ strategies comprise effective (and inherently safer)
therapy for these disorders (Elias and Wakefield, 2011). The
topical H1/2r antagonists, if they prove equally effective when
deployed topically for their human disease counterparts, could
be added to this list. Nonetheless, it now seems reasonable to
propose that H1r and H2r antagonists could be deployed
topically to treat a broad range of inflammatory dermatoses.
MATERIALS AND METHODS
(Please read Supplementary Information online for further details of
Materials and Methods).
Materials
Female albino hairless (Skh1) mice, aged 6–8 weeks, were from
Charles River Laboratories (Wilmington, MA). MCDM (KitW/KitW-v
double-heterozygous mice) and age- and gender-matched wild-type
littermates (WBB6F1) were from Jackson Labs (Bar Harbor, ME).
Ethanol and propylene glycol were from Fisher Scientific (Fairlane,
NJ); diphenhydramine chlorhydrate and cimetidine were from Sigma
(St Louis, MO); and affinity-purified, rabbit anti-mouse filaggrin,
involucrin, and loricrin antibodies were from BabCo (Richmond,
CA). Secondary biotinylated, goat anti-rabbit IgG, and ABC-perox-
idase kit were from Vector laboratories (Burlingame, CA). Anti-
proliferating cell nuclear antigen antibody (PCNA, Ki-67) was from
CalTag Laboratories (Burlingame, CA).
Experimental protocols and functional studies
Animal procedures were approved and performed in accordance with
guidelines of the Animal Studies Subcommittee (IACUC), San Fran-
cisco VA Medical Center. Mice were maintained in temperature- and
humidity-controlled rooms and given standard laboratory food and
tap water ad libitum. Barrier disruption on hairless mice was achieved
by repeated tape-stripping until a 10-fold increase in transepidermal
water loss was observed. Mice were treated topically on one or both
the flanks with 5% diphenhydramine or 5% cimetidine or vehicle
alone (propylene glycol:ethanol:water¼ 1:2:2, volume) twice daily
for 4 days. Changes in transepidermal water loss, measured with an
electrolytic water analyzer (Meeco, Warrington, PA), were measured
0, 2, and 4 hours after sequential tape stripping, resulting in a 10-fold
increase in TEWL, and percentage of barrier recovery rates was
calculated (Man et al., 1993, 2006, 2008). SC hydration was
measured as changes in electrical capacitance, and surface pH with
a flat surface electrode (Ibid.). For studies in MCDM, additional
groups of WBB6F1 mice, treated with vehicle, served as controls.
Quantification of mast cell densities
Skin biopsies were taken from normal, 30 minutes, 3 hours, and
6 hours after barrier disruption. Mast cell infiltrates in the dermis were
identified with 1% toluidine blue staining of 5-mm paraffin sections.
Pictures were taken at 20X with a Leica DM400B digital microscope
(Leica Microsystems, Buffalo Grove, IL), equipped with the LAS v4.0
software. The density of mast cells was determined on every 25 cm2
area at regions between the basement membrane and 5 cm below the
basement membrane in printed micrographs.
Statistical analyses
Data are expressed as the means±SEM. Unpaired two-tailed Student’s
t test with Welch’s correction was used to determine significant diffe-
rences when two groups were compared, and a one-way analysis of
variance with a post-Tukey Test or Dunnett post-correction was used to
determine significant differences when three or more groups were
compared.
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